Ozeroff Christopher David

Avg. Two Year Performance

No purchase track record
70% Avg. Sale Return
30% Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return0%0%0%0%0%
Purchase Success Rate0 of 10 of 10 of 10 of 10 of 1
Average Sale Return10%15%35%56%70%
Sale Success Rate4 of 65 of 66 of 66 of 64 of 6

Nuvelo Inc.

Drugs » Biotechnology

S.V.P., General Counsel:

Holdings: 50.97K shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--